An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases (PICASSO)

Roche

Status: Completed

Conditions: Colorectal Cancer

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT01343901

ML22999

Details and patient eligibility

About

This observational study will evaluate the efficacy and safety of bevacizumab as first-line treatment in participants with colorectal cancer and potentially resectable liver metastases.

Enrollment: 210 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with colorectal cancer with exclusively hepatic or hepatic and pulmonary metastases
• First-line treatment with bevacizumab for potentially resectable metastatic disease

Exclusion criteria

• Outright resectable disease
• Clearly inoperable disease
• Participation in a clinical trial evaluating a cytotoxic anticancer treatment and/or an innovative therapy

Trial design

210 participants in 1 patient group

Bevacizumab

Description:

Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.

Treatment:

Drug: Bevacizumab